Skin Diseases  >>  sorafenib  >>  Phase 3
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
sorafenib / Generic mfg.
NCT01234337 / 2010-018501-10: Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer

Checkmark EBCC P3 data
Mar 2012 - Mar 2012: EBCC P3 data
Checkmark P3 trial update (RESILIENCE study) AACR-NCI-EORTC
Nov 2011 - Nov 2011: P3 trial update (RESILIENCE study) AACR-NCI-EORTC
Completed
3
537
Canada, Japan, US, Europe, RoW
Sorafenib (Nexavar, BAY43-9006), Placebo, Capecitabine
Bayer, Onyx Therapeutics, Inc.
Breast Cancer
05/14
10/17

Download Options